China Pharma Holdings, Inc.
As of Oct 22, 2026, China Pharma Holdings is in Stage 4, the downtrend phase, now in week 2 (since Oct 15, 2026). It closed at $0.68, 91.6% below its 52-week high and below its 200-day average, which is falling.
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CPHI early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CPHI among Drug Manufacturers - Specialty & Generic63rd of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …63 | CPHI | Stage 4 · wk 2 | 18 | −5.6% |
China Pharma Holdings: quick answers
What stage is China Pharma Holdings in?
As of Oct 22, 2026, China Pharma Holdings (CPHI) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 15, 2026 and is in week 2. What the four stages mean
Is China Pharma Holdings in an uptrend?
No. China Pharma Holdings is in a Stage 4 downtrend. It trades 20.0% below its 200-day average, which is falling.
How far is China Pharma Holdings from its 52-week high?
China Pharma Holdings closed at $0.68 on Oct 22, 2026, 91.6% below its 52-week high of $8.10. Its 52-week low is $0.52.
How has China Pharma Holdings performed over the past year?
As of Oct 22, 2026, China Pharma Holdings is down 62.0% over the past year and down 43.8% so far in 2026.
Which sector and industry is China Pharma Holdings in?
China Pharma Holdings is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.